title: Treatment options for hepatitis C and the rationale for low response rates in African Americans.
abstract: Hepatitis C virus (HCV), the leading cause for liver transplantation, is emerging as1 of the infections that pose public health problems in the world since about 170 million people worldwide are infected with this virus. Inequality in addressing racial/ethnic disparities in treatment for hepatitis C is a pressing problem. HCV is more common among African Americans than among other racial groups in the United States. Although African Americans have been shown to have a lower rate of viral clearance and a higher rate of chronic hepatitis C, they may have at the same time a much lower rate of fibrosis progression compared to Caucasians. The purpose of this study is to summarize treatment options available for hepatitis C in African Americans and to describe the different mechanisms thought to be the reasons for the disparate response to treatment in African Americans.
authors: Department of Biology, Howard University, Washington, DC, USA. m_cheu@hotmail.com
authors: Cheu
authors: C
authors: Manka
authors: Ralph
authors: R
authors: Gomes
authors: Rebecca
authors: R
authors: Reviere
authors: Clarence
authors: C
authors: Lee
mesh_terms: D001741:Black or African American / Q000706:statistics & numerical data*; D000998:Antiviral Agents / Q000627:therapeutic use*; D018450:Disease Progression; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D044465:White People / Q000706:statistics & numerical data
chemical_list: D000998:Antiviral Agents; D007155:Immunologic Factors; D016898:Interferon-alpha; D012254:Ribavirin